Loading...
XTAEENDY
Market cap10mUSD
Dec 23, Last price  
277.50ILS
1D
-3.65%
1Q
31.21%
Jan 2017
-47.04%
IPO
-96.13%
Name

Endymed Ltd

Chart & Performance

D1W1MN
XTAE:ENDY chart
P/E
1,889.45
P/S
45.87
EPS
0.04
Div Yield, %
0.00%
Shrs. gr., 5y
4.39%
Rev. gr., 5y
4.30%
Revenues
23m
+6.77%
5,861,00010,546,00012,951,00014,252,00017,541,00018,453,00016,446,00014,345,00021,783,00021,334,00022,779,000
Net income
553k
-34.94%
-361,00053,000-3,830,000-3,310,000-2,701,0002,021,0001,746,000308,0005,162,000850,000553,000
CFO
-656k
L+671.76%
-394,000-2,697,000-4,901,000-777,000472,0001,193,0001,440,0001,319,0004,631,000-85,000-656,000

Profile

Endymed Ltd, a medical technology company, designs, develops, and commercializes energy based medical aesthetic treatment systems for the professional and consumer markets worldwide. Its products comprise EndyMed PRO, a multi-application treatment platform; PURE 2.0 that offers professional skin tightening, body contouring, and functional resurfacing; and 3DEEP radiofrequency technology, a solution for the treatment of skin tightening, wrinkle reduction, body contouring, texture enhancement, cellulite reduction, circumferential reduction, acne and acne scar reduction, stretch mark reduction, RF micro needling, and fractional resurfacing. The company was founded in 2007 and is based in Freehold, New Jersey.
URL
https://endymed.com/
IPO date
Jan 29, 2007
Employees
49
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
22,779
6.77%
21,334
-2.06%
21,783
51.85%
Cost of revenue
21,857
17,516
16,664
Unusual Expense (Income)
NOPBT
922
3,818
5,119
NOPBT Margin
4.05%
17.90%
23.50%
Operating Taxes
497
855
(2,511)
Tax Rate
53.90%
22.39%
NOPAT
425
2,963
7,630
Net income
553
-34.94%
850
-83.53%
5,162
1,575.97%
Dividends
Dividend yield
Proceeds from repurchase of equity
4
9
10
BB yield
-0.01%
-0.03%
-0.01%
Debt
Debt current
311
255
351
Long-term debt
2,241
2,247
2,961
Deferred revenue
391
474
Other long-term liabilities
378
57
36
Net debt
(7,184)
(8,146)
(8,006)
Cash flow
Cash from operating activities
(656)
(85)
4,631
CAPEX
(49)
(165)
(72)
Cash from investing activities
107
(154)
382
Cash from financing activities
(339)
(395)
(908)
FCF
(1,062)
937
8,530
Balance
Cash
9,736
10,648
11,318
Long term investments
Excess cash
8,597
9,581
10,229
Stockholders' equity
(3,984)
(5,146)
(5,997)
Invested Capital
20,911
21,549
21,922
ROIC
2.00%
13.63%
34.51%
ROCE
5.45%
23.28%
32.14%
EV
Common stock shares outstanding
13,807
14,027
13,938
Price
2.89
18.25%
2.44
-65.86%
7.16
152.88%
Market cap
39,902
16.39%
34,282
-65.64%
99,782
156.60%
EV
33,327
26,740
92,448
EBITDA
1,368
4,325
5,626
EV/EBITDA
24.36
6.18
16.43
Interest
36
37
44
Interest/NOPBT
3.90%
0.97%
0.86%